by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Australian Journal of Pharmacy : October 2006
McNABB WL7941 Why Caltrate? Calcium has a place in the treatment of osteoporosis. Calcium intake is an important adjunct in postmenopausal osteoporosis treatment.1 Why Caltrate? Bisphosphonates, SERMs and HRT are first line therapies for osteoporosis. Increased calcium intake, from dietary sources or supplementation, should always be adjunctive therapy in the treatment of postmenopausal osteoporosis.1 •Bisphosphonates, SERMs† postmenopausal women,2-4 and HRT‡ inhibit bone resorption in but do not replace calcium • Calcium supplements are recommended for women taking some of these therapies, when dietary calcium is inadequate2-3 • 84% of Australian women 55 years and over do not get enough dietary calcium5 One way to make sure your osteoporosis patients have adequate calcium intake is to recommend a calcium supplement like Caltrate. * ?Each tablet contains 600mg of calcium ?60 to 75% of Australian Adults RDI††6 ?Caltrate Plus contains vitamin D plus 4 bone fortifying minerals ?Lactose and gluten free ?Caltrate Plus is affordable at 20c per day So, if you’re treating your patient for osteoporosis consider Caltrate. Assists in preventing and treating osteoporosis. Wyeth Consumer Healthcare Pty Ltd ABN 75 000 477 154. 17-19 Solent Circuit, Norwest Business Park, Baulkham Hills NSW 2153. Ph: (02) 9762 6100. Fax: (02) 9023 0010. Toll free 1800 283 195. www.caltrate.com.au 1. Sambrook PN, et al. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit.Med J Aust 2002;176:S1-S16. 2. Fosamax Product Information. MIMS Annual, 2004. 3. Evista Product Information. MIMS Annual, 2004. 4. Premia Product Information. MIMS Annual, 2004. 5. Australian Bureau of Statistics. National Nutrition Survey. Nutrient intakes and physical measurements, Australia 1995. (Cat. No: 4805.0). 6. National Health and Medical Research Council, Recommended Dietary Intakes for use in Australia. Canberra AGPS 1991.® Registered Trademark. Fosamax® is a registered trade mark of Merck Sharpe and Dohme. Evista® is a registered trade mark of Eli Lilly. Actonel® is a registered trade mark of Sonofi Aventis. † Selective Oestrogen Receptor Modulators. ‡ Hormone Replacement Therapy. *Bisphosphonates and Caltrate must be administered at different times of the day – bisphosphonates 30 minutes before food; Caltrate after a meal. †† Except pregnant or lactating. For full list of ingredients see label.